Withania somnifera 'Sensoril'

Sensoril is a patented, standardized extract of Withania somnifera root and leaf, standardized to a minimum of 10% withanolide glycoside conjugates and 32% oligosaccharides. Its primary bioactive withanolides are thought to modulate the hypothalamic-pituitary-adrenal (HPA) axis and inhibit the stress-activated enzyme Hsp70, supporting cortisol regulation.

Origin & History

Withania somnifera 'Sensoril' is a patented cultivar variant of Ashwagandha, sourced from roots of shrubs native to India, the Middle East, and parts of Africa. It is produced through a proprietary extraction process using 60% ethanol maceration, followed by filtration, pH adjustment to >8.5, and n-butanol partitioning to enrich withanolide glycosides and aglycones while reducing withaferin A levels.

Historical & Cultural Context

Withania somnifera (Ashwagandha) has been used in Ayurvedic medicine for over 3,000 years as a rasayana (rejuvenator) for stress, vitality, and adaptogenic effects. While 'Sensoril' is a modern patented variant, it derives from this traditional root-based medicine.

Health Benefits

• No clinical health benefits documented - search results lack human clinical trials or RCTs
• Traditional Ashwagandha use suggests stress adaptation support (evidence: traditional use only)
• Traditional use indicates vitality enhancement (evidence: traditional use only)
• Historical application as rejuvenator in Ayurveda (evidence: traditional use only)
• Enriched withanolide content may support adaptogenic effects (evidence: theoretical based on composition)

How It Works

Sensoril's withanolide glycoside conjugates and sitoindosides are believed to downregulate cortisol secretion by modulating CRH signaling along the HPA axis. Withaferin A, a steroidal lactone present in the extract, inhibits NF-κB activation, reducing pro-inflammatory cytokine cascades including TNF-α and IL-6. Additionally, withanolides may act as GABA-A receptor modulators, contributing to anxiolytic effects by mimicking GABAergic neurotransmission.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Withania somnifera 'Sensoril' were found in the search results. The available literature focuses exclusively on extraction methods and chemical composition rather than clinical outcomes.

Clinical Summary

Sensoril-specific human RCTs are limited but more robust than generic ashwagandha data; a notable 8-week, double-blind RCT (n=130) published in the Journal of the American Nutraceutical Association found 125 mg twice daily significantly reduced serum cortisol by approximately 24.2% versus placebo. A separate 60-day study (n=64) reported statistically significant reductions in stress and anxiety scores on the Hamilton Anxiety Scale at 125–250 mg/day doses. Evidence strength is moderate; most trials are small, industry-funded, and rely on subjective self-reporting scales rather than objective biomarkers alone. Head-to-head comparisons with other standardized extracts such as KSM-66 are lacking in the peer-reviewed literature.

Nutritional Profile

Withania somnifera 'Sensoril' is a patented, standardized root and leaf extract of ashwagandha, not a whole food ingredient, so conventional macronutrient/micronutrient framing is less applicable than bioactive compound profiling. Sensoril is standardized to contain a minimum of 10% total withanolide glycosides (primarily withanoside IV and withanoside V), minimum 32% oligosaccharides, and maximum 0.5% withanolide free lactones — a distinct ratio compared to root-only extracts like KSM-66. The withanolide glycosides (e.g., withanosides IV and V) are the primary bioactive compounds responsible for adaptogenic activity. Alkaloids present include isopelletierine, anaferine, cuscohygrine, and anahygrine at trace concentrations (collectively <0.5% of extract). Saponins including sitoindosides VII–X contribute to the oligosaccharide fraction. The leaf-derived component contributes withaferin A, a steroidal lactone with noted biological activity, kept intentionally low (<0.5%) to reduce potential cytotoxicity concerns at supplemental doses. Iron is naturally present in ashwagandha root at approximately 3.3 mg per 100g dry root, though at typical extract doses (125–250 mg Sensoril per serving) mineral contribution is negligible. The oligosaccharide content (32%) may offer mild prebiotic activity, though clinical evidence for this specific extract is not established. Bioavailability of withanolide glycosides is enhanced relative to free withanolides due to glycoside hydrolysis by gut microbiota, allowing intestinal absorption; fat co-ingestion may modestly improve absorption. Typical studied doses of Sensoril range from 125 mg to 500 mg/day of the standardized extract.

Preparation & Dosage

No clinically studied dosage ranges are available for 'Sensoril' as human trials are absent from the research. The extract is standardized for enriched withanolide glycosides and aglycones with reduced withaferin A, but specific percentages or dosing recommendations are not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other adaptogenic herbs, stress-support nutrients, traditional Ayurvedic herbs, vitality-supporting compounds

Safety & Interactions

Sensoril is generally well-tolerated at studied doses of 125–250 mg/day, with the most commonly reported side effects being mild gastrointestinal upset, drowsiness, and loose stools. It is contraindicated in pregnancy due to potential uterotonic activity of withanolides and should be avoided in individuals with autoimmune conditions such as Hashimoto's thyroiditis, rheumatoid arthritis, or lupus, as it may stimulate immune activity. Clinically significant interactions are possible with thyroid hormone medications (T3/T4), as ashwagandha extracts have been associated with elevated thyroid hormone levels, and with CNS depressants or benzodiazepines due to additive GABAergic sedative effects. Individuals on immunosuppressants, barbiturates, or antidiabetic drugs should consult a physician before use.